APA (7th ed.) Citation

G, G., Y, J., ZI, O., V, N., A, C., V, T., . . . U, S. (2026). Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. Bladder cancer (Amsterdam, Netherlands), 12(1), 23523735261437911. https://doi.org/10.1177/23523735261437911

Chicago Style (17th ed.) Citation

G, Gebrael, et al. "Treatment Patterns and Outcomes with Second-line Therapies in Patients with Advanced Urothelial Carcinoma Previously Treated with First-line Enfortumab Vedotin with Pembrolizumab." Bladder Cancer (Amsterdam, Netherlands) 12, no. 1 (2026): 23523735261437911. https://doi.org/10.1177/23523735261437911.

MLA (9th ed.) Citation

G, Gebrael, et al. "Treatment Patterns and Outcomes with Second-line Therapies in Patients with Advanced Urothelial Carcinoma Previously Treated with First-line Enfortumab Vedotin with Pembrolizumab." Bladder Cancer (Amsterdam, Netherlands), vol. 12, no. 1, 2026, p. 23523735261437911, https://doi.org/10.1177/23523735261437911.